Studies on the bioequivalence of domestic terazosin tablet in healthy volunteers
Jun Chen
Abstract
Jun Chen
Abstract
OBJECTIVE To observe the bioavailability of domestic terazosin tablet and imported tablet.METHODS A single oral dose of 2 mg domestic or imported terazosin tablet was given to 20 healthy volunteers in a randomized crossover study.Terazosin concentrations in plasma were determined by HPLC method.RESULTS The main pharmacokinetics of the two products were as follow: t max (1.08±0.54) and (1.18±0.37) h, c max (44.44±11.72) and (41.28±9.77) μg·L -1 ,MRT (9.48±0.76) and (9.36± 0.90 ) h, t 1/2 (10.10±1.45) and (9.77±1.76) h,AUC 0~36 h (372.82±97.44) and (361.57±83.21) μg·h·L -1 respectively.The relative bioavailability of domestic to imported tablets was (103±13)%.CONCLUSION There was no significant difference between the parameters of two products ( P 0.5).The results demonstrated that the two preparations were bioequivalent.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE To observe the bioavailability of domestic terazosin tablet and imported tablet.METHODS A single oral dose of 2 mg domestic or imported terazosin tablet was given to 20 healthy volunteers in a randomized crossover study.Terazosin concentrations in plasma were determined by HPLC method.RESULTS The main pharmacokinetics of the two products were as follow: t max (1.08±0.54) and (1.18±0.37) h, c max (44.44±11.72) and (41.28±9.77) μg·L -1 ,MRT (9.48±0.76) and (9.36± 0.90 ) h, t 1/2 (10.10±1.45) and (9.77±1.76) h,AUC 0~36 h (372.82±97.44) and (361.57±83.21) μg·h·L -1 respectively.The relative bioavailability of domestic to imported tablets was (103±13)%.CONCLUSION There was no significant difference between the parameters of two products ( P 0.5).The results demonstrated that the two preparations were bioequivalent.
Key concepts: Bioequivalence, Bioavailability, Terazosin, Crossover study, Pharmacokinetics, Pharmacology, Significant difference, Plasma concentration